We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Generics Still a Quiet Profit Engine for Cardinal Health?
Read MoreHide Full Article
Key Takeaways
Cardinal Health says generics remains an important, relatively steady profit contributor in Pharma.
Generic volume growth topped the 2-3% long-term planning assumption in fiscal 2026.
New generic launches, conversions and stable Red Oak dynamics are expected to support fiscal 2027 profits.
Generics continues to function as an important, relatively steady profit contributor for Cardinal Health’s (CAH - Free Report) Pharma business, even though its revenue impact can be uncertain due to changes in brand pricing, IRA-related adjustments and GLP-1 volumes. In fiscal 2026, generic volume growth exceeded Cardinal Health’s long-term planning assumption of 2-3%, creating what management described as some of the company’s more profitable volume growth. Management expects generic volumes to moderate toward normalized levels in fiscal 2027, but still views the category as a meaningful earnings driver.
The economics are particularly attractive when branded drugs convert to generics. CFO Aaron Alt said Cardinal Health is focused on the profitability associated with generic conversions and noted that the company received an additional benefit from these conversions in the fourth quarter of fiscal 2026.
Management expects some of this benefit to contribute to Pharma segment profit in fiscal 2027. This highlights Cardinal Health’s focus on capturing the profitability benefits of generic conversions while maintaining attractive margins as its product mix changes.
The Red Oak-enabled generics program provides another layer of consistency. Cardinal Health expects fiscal 2027 to benefit from new generic item launches, including fiscal 2026 carryover products, alongside continued consistent market dynamics within the Red Oak program. The company also maintains a strategic relationship with CVS through Red Oak, reinforcing the program’s importance within its broader pharmaceutical ecosystem.
Overall, generics appears to be a stable margin contributor rather than a headline growth engine. With Pharma segment profit expected to grow 8-11% in fiscal 2027, continued strength in generic and brand volumes is explicitly identified as a key driver. The combination of higher generic volumes, favorable brand-to-generic conversions and stable Red Oak market dynamics should therefore continue to support Pharma profitability, even as revenue growth normalizes.
Peer Updates
McKesson’s (MCK - Free Report) generics portfolio remained a meaningful contributor to North American Pharmaceutical profitability in the first quarter of fiscal 2027. Prescription transaction volumes increased 5%, although revenues were partly constrained by branded-to-generic conversions. Those conversions supported gross profit, while the timing of new branded and generic product launches helped drive the segment’s 19% operating-profit growth to $894 million. Management also highlighted the strength of ClarusONE, McKesson’s generic sourcing program, which continues to create customer value and support supply stability. Although the company did not disclose a standalone generic margin, management noted that product mix, including generics, influences segment margins, as operating profit grew substantially faster than revenues.
Cencora (COR - Free Report) emphasizes broader pharmaceutical distribution, specialty growth and biosimilars. U.S. Healthcare Solutions revenues increased 5% to $74.9 billion, while operating income rose 16% to $966 million, with strength in specialty and underlying utilization supporting profitability.
Management specifically characterized Part B biosimilars as an incremental profit opportunity, given Cencora’s larger role through distribution, GPO and MSO services surrounding physician-administered products. By contrast, Part D biosimilar conversions can reduce revenues with less meaningful profit improvement. Thus, Cencora’s generics-related earnings opportunity appears more service- and mix-driven than volume-driven.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have gained 19.4% so far this year compared with the industry’s 6.5% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 19.2X, above the industry average. However, it is trading lower than its five-year high of 22.19X. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2027 earnings implies an 11.5% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Bigstock
Is Generics Still a Quiet Profit Engine for Cardinal Health?
Key Takeaways
Generics continues to function as an important, relatively steady profit contributor for Cardinal Health’s (CAH - Free Report) Pharma business, even though its revenue impact can be uncertain due to changes in brand pricing, IRA-related adjustments and GLP-1 volumes. In fiscal 2026, generic volume growth exceeded Cardinal Health’s long-term planning assumption of 2-3%, creating what management described as some of the company’s more profitable volume growth. Management expects generic volumes to moderate toward normalized levels in fiscal 2027, but still views the category as a meaningful earnings driver.
The economics are particularly attractive when branded drugs convert to generics. CFO Aaron Alt said Cardinal Health is focused on the profitability associated with generic conversions and noted that the company received an additional benefit from these conversions in the fourth quarter of fiscal 2026.
Management expects some of this benefit to contribute to Pharma segment profit in fiscal 2027. This highlights Cardinal Health’s focus on capturing the profitability benefits of generic conversions while maintaining attractive margins as its product mix changes.
The Red Oak-enabled generics program provides another layer of consistency. Cardinal Health expects fiscal 2027 to benefit from new generic item launches, including fiscal 2026 carryover products, alongside continued consistent market dynamics within the Red Oak program. The company also maintains a strategic relationship with CVS through Red Oak, reinforcing the program’s importance within its broader pharmaceutical ecosystem.
Overall, generics appears to be a stable margin contributor rather than a headline growth engine. With Pharma segment profit expected to grow 8-11% in fiscal 2027, continued strength in generic and brand volumes is explicitly identified as a key driver. The combination of higher generic volumes, favorable brand-to-generic conversions and stable Red Oak market dynamics should therefore continue to support Pharma profitability, even as revenue growth normalizes.
Peer Updates
McKesson’s (MCK - Free Report) generics portfolio remained a meaningful contributor to North American Pharmaceutical profitability in the first quarter of fiscal 2027. Prescription transaction volumes increased 5%, although revenues were partly constrained by branded-to-generic conversions. Those conversions supported gross profit, while the timing of new branded and generic product launches helped drive the segment’s 19% operating-profit growth to $894 million. Management also highlighted the strength of ClarusONE, McKesson’s generic sourcing program, which continues to create customer value and support supply stability. Although the company did not disclose a standalone generic margin, management noted that product mix, including generics, influences segment margins, as operating profit grew substantially faster than revenues.
Cencora (COR - Free Report) emphasizes broader pharmaceutical distribution, specialty growth and biosimilars. U.S. Healthcare Solutions revenues increased 5% to $74.9 billion, while operating income rose 16% to $966 million, with strength in specialty and underlying utilization supporting profitability.
Management specifically characterized Part B biosimilars as an incremental profit opportunity, given Cencora’s larger role through distribution, GPO and MSO services surrounding physician-administered products. By contrast, Part D biosimilar conversions can reduce revenues with less meaningful profit improvement. Thus, Cencora’s generics-related earnings opportunity appears more service- and mix-driven than volume-driven.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have gained 19.4% so far this year compared with the industry’s 6.5% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 19.2X, above the industry average. However, it is trading lower than its five-year high of 22.19X. CAH carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2027 earnings implies an 11.5% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.